Peptide Drug Conjugates Market Report 2026

Peptide Drug Conjugates Market Overview

• Peptide Drug Conjugates market size has reached to $3.64 billion in 2025 • Expected to grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 15.3% • Growth Driver: Surge In Personalized Treatments Fueling The Growth Of The Market Due To Advancements In Genomics And Targeted Therapies • Market Trend: Development Of Tumor-Selective Therapies Driving Precision In Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Peptide Drug Conjugates Market?

Peptide drug conjugates are targeted therapies that combine peptides with cytotoxic drugs to increase treatment precision. The peptide, which binds specifically to cell receptors, is attached to the drug, enabling it to directly target diseased cells such as tumors. This approach improves the drug's stability, selectivity, and bioavailability, enhancing its overall therapeutic effectiveness while minimizing damage to healthy tissues. The main types of peptide drug conjugates include therapeutic and diagnostic. A peptide drug conjugate (PDC) therapeutic is a targeted treatment where a peptide is attached to a drug, often a cytotoxic agent, to deliver the drug directly to cancer cells or other diseased tissue. It is used for oncology, immunology, infectious diseases, and others, and can be administered through intravenous, subcutaneous, and other routes. It is used by various end users such as hospitals, clinics, pharmacies, and others.

What Is The Peptide Drug Conjugates Market Growth Forecast?

The peptide drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $7.44 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to rising demand for precision therapies, advancements in linker technologies, expansion of cancer indications, increased investment in peptide drug development, growth of diagnostic-targeted conjugates. Major trends in the forecast period include growing development of targeted peptide conjugates, increasing use in oncology therapeutics, rising focus on improved drug selectivity, expansion of diagnostic peptide conjugates, increasing clinical trials for novel conjugates.

Global Peptide Drug Conjugates Market Segmentation

1) By Type: Therapeutic, Diagnostic 2) By Therapy Area: Oncology, Immunology, Infectious Diseases, Other Therapy Areas 3) By Route of Administration: Intravenous, Subcutaneous, Other Routes Of Administration 4) By End User: Hospitals, Clinics, Pharmacies, Other End Users Subsegments: 1) By Therapeutic: Monoclonal Antibodies (mAbs), Cytotoxic Agents, Immunomodulatory Agents, Targeted Therapies 2) By Diagnostic: Imaging Agents, Biomarker Targeting Agents

What Is The Driver Of The Peptide Drug Conjugates Market?

The growing demand for personalized treatments is anticipated to drive the growth of the peptide drug conjugates market in the coming years. Personalized treatments are medical therapies tailored to an individual’s unique genetic makeup, lifestyle, and disease characteristics to achieve the most effective outcome. Personalized treatments are rising due to advances in genomics that help identify individual disease markers, allowing for more precise and effective therapies. Personalized treatments enhance peptide drug conjugates by allowing the choice of specific peptides that target unique disease biomarkers in patients, leading to more precise and effective drug delivery. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition, a US-based non-profit organization, the FDA authorized 16 novel customized medicines for patients with rare disorders in 2023, a substantial rise from the 6 that were authorized in 2022. Therefore, the growing demand for personalized treatments will boost the growth of the peptide drug conjugates industry.

Key Players In The Global Peptide Drug Conjugates Market

Major companies operating in the peptide drug conjugates market are PeptiDream Incorporated, Cybrexa Therapeutics Inc., Oncopeptides Aktiebolag (AB), Soricimed Biopharma Inc., Angiochem Inc., ADC Therapeutics SA, Ambrx Inc., Araris Biotech AG, Adcytherix SA, ProteinQure Incorporated, Esperance Pharmaceuticals Inc., Protagonist Therapeutics Inc., PepGen Corporation, Curium US LLC, AstraZeneca PLC, Novartis AG, Italfarmaco Società per Azioni, BioNTech SE, Theratechnologies Inc., Zealand Pharma A/S

Global Peptide Drug Conjugates Market Trends and Insights

Major companies operating in the peptide drug conjugates market are focusing on developing advanced treatment options, such as tumor-selective peptide drug conjugates, to enhance treatment precision. Tumor-selective peptide drug conjugates are targeted treatments that utilize peptides engineered to bind specifically to cancer cells, enabling the direct delivery of cytotoxic agents to tumors while reducing damage to healthy tissue. For instance, in March 2025, Cybrexa Therapeutics, a US-based oncology biotechnology company, announced new preclinical data from its alphalex technology. The data highlighted the efficacy of Cybrexa's antigen-agnostic peptide-drug conjugate (PDC) platform in delivering potent microtubule inhibitors directly to tumor cells. This approach effectively suppresses tumor growth and induces a durable anti-tumor immune response. The findings demonstrate the potential of Cybrexa's technology for enhancing cancer treatment.

What Are Latest Mergers And Acquisitions In The Peptide Drug Conjugates Market?

In May 2023, Bayer AG, a Germany-based pharmaceutical company, partnered with Bicycle Therapeutics to develop radioconjugates for multiple oncology targets. As a result of the partnership, Bicycle will utilize its phage platform to discover highly selective bicyclic peptides. Bayer will be responsible for advancing these candidates through preclinical and clinical development, as well as managing manufacturing and commercialization, to deliver targeted radiotherapy solutions for unmet needs in oncology. Bicycle Therapeutics is a UK-based manufacturer of peptide drug conjugates.

Regional Insights

North America was the largest region in the peptide drug conjugates market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Peptide Drug Conjugates Market?

The peptide drug conjugates market consists of revenues earned by entities by providing services such as conjugation services, preclinical testing, formulation development, target discovery, and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide drug conjugates market also includes sales of peptide payload linkers, synthetic peptides, peptide targeting ligands, and drug delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Peptide Drug Conjugates Market Report 2026?

The peptide drug conjugates market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peptide drug conjugates industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.